Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

2378 - Intrinsic and Extrinsic regulation of PD-L2 Expression by transcription factor STAT3 or c-FOS in Oncogene-Driven Non-Small Cell Lung Cancer

Date

20 Oct 2018

Session

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

Presenters

Daisuke Shibahara

Citation

Annals of Oncology (2018) 29 (suppl_8): viii400-viii441. 10.1093/annonc/mdy288

Authors

D. Shibahara1, K. Tanaka2, E. Iwama2, N. Kubo2, K. Ota3, K. Azuma4, T. Harada2, J. Fujita1, Y. Nakanishi5, I. Okamoto2

Author affiliations

  • 1 Infectious Disease, Respiratory, And Digestive Medicine,, Ryukyu University Hospital, 903-0125 - Okinawa/JP
  • 2 Respiratory Medicine, Kyushu University Hospital, 812-8582 - FUKUOKA/JP
  • 3 Respiratory, Kyushu University Hospital, 812-8582 - FUKUOKA/JP
  • 4 Respirology, Neurology, And Rheumatology, kurume university school of medicine, 812-8582 - Fukuoka/JP
  • 5 Research Institute For Diseases Of The Chest, Kyushu University Hospital, 812-8582 - FUKUOKA/JP
More

Resources

Abstract 2378

Background

Treatment with antibodies that target programmed cell death 1 (PD-1) or its ligand programmed death ligand 1 (PD-L1) has demonstrated durable efficacy for various malignant tumors. Programmed death ligand 2 (PD-L2), which is another ligand of PD-1, has recently been shown to be implicated in tumor immune escape. The regulation of PD-L2 expression in tumor cells has remained unclear, however. We here examined intrinsic and extrinsic regulation of PDL2 expression in NSCLC.

Methods

PD-L2 expression was evaluated by reverse transcription and real-time polymerase chain reaction analysis and by flow cytometry.

Results

BEAS-2B cells stably expressing an activated mutant form of the epidermal growth factor receptor (EGFR) or the EML4-ALK fusion oncoprotein manifested increased expression of PD-L2 at both mRNA and protein levels. Furthermore, treatment of NSCLC cell lines that harbor such driver oncogenes with corresponding EGFR or ALK tyrosine kinase inhibitors or depletion of EGFR or ALK by siRNA transfection suppressed expression of PD-L2, demonstrating that activating EGFR mutations or EML4-ALK fusion intrinsically induce PD-L2 expression. We also found that interferon-γ extrinsically induced expression of PD-L2 via STAT1 signalingin NSCLC cells. Oncogene-driven expression of PD-L2 in NSCLC cells was inhibited by knockdown of the transcription factors STAT3 or c-FOS. Interferon-γ also activated STAT3 and c-FOS. Knockdown of STAT3 or c-FOS decreased Interferon-γ-induced expression of PD-L2, suggesting that these proteins may also contribute to the extrinsic induction of PD-L2 expression.

Conclusions

Expression of PD-L2 is induced intrinsically by activating EGFR mutations or EML4-ALK fusion as well as extrinsically by interferon-γ, with STAT3 and c-FOS possibly contributing to both intrinsic and extrinsic pathways. Our results thus provide insight into the complexity of tumor immune escape in NSCLC.

Clinical trial identification

Legal entity responsible for the study

an individual person.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

K. Azuma: Personal fees: AstraZeneca; Grants and personal fees: Boehringer Ingelheim, Ono Pharmaceutical, MSD Oncology, Bristol-Myers Squibb, and Chugai Pharma outside the submitted work. I. Okamoto: Grants and personal fees: AstraZeneca, Taiho Pharmaceutical, Boehringer Ingelheim, Ono Pharmaceutical, MSD Oncology, Lilly, Bristol-Myers Squibb, Chugai Pharma; Grants: Astellas Pharma Novartis; Personal fees: Pfizer outside the submitted work. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.